Valentina Ruvalcaba
Oncology · Chula Vista, CANPI 1669830451
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,141 of the $6,191 with a category attached, or 83.0%. It is spread thinly across 53 manufacturers, the largest accounting for just 7.8% — the pattern of someone who eats at a lot of different presentations. Among oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $26.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$482
- Merck$443
- Johnson & Johnson$441
- Novartis$365
- Pfizer$357
- Pharmacyclics LLC, An Abbvie Company$293
- plus $4K from 47 others
What the payments were for
- Food & beverage$5,14183%
- Education$88314%
- Other$1673%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,191 in reported general payments places this provider in the 95th percentile of 23 oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 34 | $541,775 |
| XtandiEnzalutamide | 18 | $246,464 |
| LynparzaOlaparib | 12 | $200,222 |
| Pazopanib Hcl | 13 | $68,074 |
| SprycelDasatinib | 11 | $52,785 |
| Imatinib Mesylate | 23 | $27,484 |
| Letrozole | 180 | $5,014 |
| Anastrozole | 37 | $542 |
| Dexamethasone | 14 | $470 |
| Hydroxyurea | 20 | $359 |
| Bicalutamide | 12 | $352 |
| Alendronate Sodium | 54 | $349 |
| Prochlorperazine Maleate | 18 | $291 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $213 |
| Tamsulosin Hcl | 16 | $212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance | $357 | $541,77534 claims |
| Astellas Pharma US IncXtandi | $84 | $246,46418 claims |
| AstraZenecaLynparza | $482 | $200,22212 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $105 | $52,78511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 23 oncology providers in California.
Other oncology in Chula Vista
- Jacquelyn MitchellPalo Alto$17K
- Vivian HuangSan Francisco$3K
- Hea YoonLos Angeles$1K
- Keni HoriuchiFairfield$1K
- Carolyn McManusActon$1K
- Barbara BakerBurbank$1K
- Alia BanaSanta Clara$908
- Susan Moon LabriolaLos Angeles$707
- Frank DelaramaPalo Alto$381
- Marlon SariaSanta Monica$313
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.